• 1
    Kannel WB, Dawber TR, Thomas HE Jr, McNamara PM. Comparison of serum lipids in the prediction of coronary heart disease. Framingham Study indicates that cholesterol level and blood pressure are major factors in coronary heart disease; effect of obesity and cigarette smoking also noted. RI Med J 1965; 48:24350.
  • 2
    Narayan KM, Ali MK, Koplan JP. Global noncommunicable diseases – where worlds meet. N Engl J Med 2010; 363:11968.
  • 3
    Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:21723.
  • 4
    World Health Organization, Mathers C, Stevens G, Mascarenhas M. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva, Switzerland: World Health Organization, 2009. Available at (accessed 12 January 2010).
  • 5
    Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:198392.
  • 6
    Bestehorn K, Wahle K, Kirch W. Stroke risk screening of adults with hypertension: prospective cross-sectional study in primary care. Clin Drug Investig 2008; 28:2819.
  • 7
    Canadian Health Measures Survey: blood pressure in adults. Statistics Canada. The Daily. 17 February 2010. Available at (accessed 30 December 2010).
  • 8
    Lee DS, Chiu M, Manuel DG et al. Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors. CMAJ 2009; 181:E5566.
  • 9
    Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology 2009; 72:172734.
  • 10
    O'Donnell MJ, Xavier D, Liu L et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case–control study. Lancet 2010; 376:11223.
  • 11
    Ezzati M, Hoorn SV, Rodgers A et al. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003; 362:27180.
  • 12
    Danaei G, Rimm EB, Oza S, Kulkarni SC, Murray CJ, Ezzati M. The promise of prevention: the effects of four preventable risk factors on national life expectancy and life expectancy disparities by race and county in the United States. PLoS Med 2010; 23 (7): e1000248.
  • 13
    Rubinstein A, Colantonio L, Bardach A et al. Estimate of the cardiovascular disease burden attributable to modifiable risk factors in Argentina. Rev Panam Salud Publica 2010; 27:23745.
  • 14
    Longstreth WT Jr, Dulberg C, Manolio TA et al. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2002; 33:237682.
  • 15
    Gouw AA, van der Flier WM, Fazekas F et al. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability Study. Stroke 2008; 39:141420.
  • 16
    Tsivgoulis G, Alexandrov AV, Wadley VG et al. Association of higher diastolic blood pressure levels with cognitive impairment. Neurology 2009; 73:58995.
  • 17
    Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274:184651.
  • 18
    Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277:8137.
  • 19
    Prins ND, van Dijk EJ, den Heijer T et al. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005; 128:203441.
  • 20
    Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348:121522.
  • 21
    Lopez OL, Jagust WJ, Dulberg C et al. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol 2003; 60:13949.
  • 22
    Knopman DS, Roberts R. Vascular risk factors: imaging and neuropathologic correlates. J Alzheimers Dis 2010; 20:699709.
  • 23
    Aguero-Torres H, Kivipelto M, von Strauss E. Rethinking the dementia diagnoses in a population-based study: what is Alzheimer's disease and what is vascular dementia? A study from the kungsholmen project. Dement Geriatr Cogn Disord 2006; 22:2449.
  • 24
    Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358:103341.
  • 25
    Gorelick PB, William M. Feinberg lecture: cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke 2005; 36:8759.
  • 26
    Pimenta E, Oparil S, Medscape Prehypertension: epidemiology, consequences and treatment. Nat Rev Nephrol 2010; 6:2130.
  • 27
    Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:108697.
  • 28
    Cushman WC, Ford CE, Einhorn PT et al. Blood pressure control by drug group in the antihypertensive and lipid lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2008; 10:75160.
  • 29
    Einhorn PT, Davis BR, ALLHAT Cooperative Research Group et al. ALLHAT: still providing correct answers after 7 years. Curr Opin Cardiol 2010; 25:35565.
  • 30
    Tu JV. Reducing the global burden of stroke: INTERSTROKE. Lancet 2010; 376:745.
  • 31
    Gentil A, Bejot Y, Lorgis L et al. Comparative epidemiology of stroke and acute myocardial infarction: the Dijon Vascular project (Diva). J Neurol Neurosurg Psychiatry 2009; 80:100611.
  • 32
    Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
  • 33
    The ACCORD Study Group, Cushman WC, Evans GW et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:157585.
  • 34
    Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. Art No.: CD004349. DOI: DOI: 10.1002/14651858.CD004349.pub2. Available at (accessed 30 December 2010).
  • 35
    Sokol SI, Kapoor JR, Foody JM. Blood pressure reduction in the primary and secondary prevention of stroke. Curr Vasc Pharmacol 2006; 4:15560.
  • 36
    MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:76574.
  • 37
    Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35:77685.
  • 38
    Khan NA, Hemmelgarn B, Herman RJ et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 – therapy. Can J Cardiol 2008; 24:46575.
  • 39
    Flack JM. Epidemiology and unmet needs in hypertension. J Manag Care Pharm 2007; 13:S28.
  • 40
    Girerd X, Giral P. Risk stratification for the prevention of cardiovascular complications of hypertension. Curr Med Res Opin 2004; 20:113742.
  • 41
    Perry HM Jr, David BR, Price TR et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000; 284:46571.
  • 42
    Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:188798.
  • 43
    Jones C, Simpson SH, Mitchell D et al. Enhancing hypertension awareness and management in the elderly: lessons learned from the Airdrie Community Hypertension Awareness and Management Program (A-CHAMP). Can J Cardiol 2008; 24:5617.
  • 44
    Leenen FH, Dumais J, McInnis NH et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008; 178:14419.
  • 45
    Gorelick PB. Challenges of designing trials for the primary prevention of stroke. Stroke 2009; 40 (Suppl.): S824.
  • 46
    Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14:328.
  • 47
    Boyle R. Strategies for assessing cardiovascular risk in asymptomatic populations. Heart 2010; 96:901.
  • 48
    Fuster V. An ounce of prevention. Nat Rev Cardiol 2009; 6:5534.
  • 49
    Alwan A, Maclean DR, Mandil A. Assessment of National Capacity for the Prevention and Control of Noncommunicable Diseases: The Report of a Global Survey, WHO/MNC/01.2. Geneva: World Health Organization, 2001.
  • 50
    Young TK, Hachinski V. The population approach to stroke prevention: a Canadian perspective. Clin Invest Med 2003; 26:7886.
  • 51
    Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. Lancet 2002; 360:190313.
  • 52
    Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertension 2006; 47:34551.
  • 53
    Tocci G, Giovannelli F, Sciarretta S, Ferrucci A, Zito GB, Volpe M. Management of hypertension and stroke prevention: results of the Italian cardiologist survey. Int J Clin Pract 2009; 63:20716.
  • 54
    Burnier M, Brown RE, Ong SH, Keskinaslan A, Khan ZM. Issues in blood pressure control and the potential role of single pill combination therapies. Int J Clin Pract 2009; 63:7908.
  • 55
    Kaczorowski JA, Chambers LW, Dolovich L et al. Improving cardiovascular health at the population level: a 39 community cluster-randomized trial of the Cardiovascular Health Awareness Program (C-CHAP). Stroke 2010; 41:e474.
  • 56
    Lai LL. Community pharmacy-based hypertension disease – management program in a Latino/Hispanic-American population. Consult Pharm 2007; 22:4116.
  • 57
    The National Stroke Foundation. Australia, 2010. Available at (accessed 30 December 2010).
  • 58
    Guillaume L, Cooper R, Avery A et al. Supplementary prescribing by community and primary care pharmacists: an analysis of PACT data, 2004–2006. J Clin Pharm Ther 2008; 33:116.
  • 59
    Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized trial. JAMA 2006; 296:256371.
  • 60
    Sacco WP, Malone JL, Morrison AD, Friedman A, Wells K. Effect of a brief, regular telephone intervention by paraprofessionals for type 2 diabetes. J Behav Med 2009; 32:34959.
  • 61
    Halpern SD, Ubel PA, Berlin JA, Asch DA. Randomized trial of 5 dollars versus 10 dollars monetary incentives, envelope size, and candy to increase physician response rates to mailed questionnaires. Med Care 2002; 40:8349.
  • 62
    Volpp KG. Paying people to lose weight and stop smoking. LDI Issue Brief 2009; 14:14.
  • 63
    Wall J, Mhurchu CN, Blakely T, Rodgers A, Wilton J. Effectiveness of monetary incentives in modifying dietary behaviour: a review of randomized, controlled trials. Nutr Rev 2006; 64:51831.
  • 64
    Volpp KG, Troxel AB, Pauly MV et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med 2009; 360:699709.
  • 65
    O'Kane ME. Performance-based measures: the early results are in. J Manag Care Pharm 2007; 13 (Suppl. B): S36.
  • 66
    Mehrotra A, Pearson SD, Coltin KL et al. The response of physician groups to P4P incentives. Am J Manag Care 2007; 13:24955.